Pharmacological Research - Modern Chinese Medicine最新文献

Introduction

Methods

Results

Discussion

Introduction

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age. Current management strategies only provide symptomatic relief, and there is a need for better treatments. Gamma-oryzanol, a dietary component found in rice bran oil, has been shown to be effective in increasing insulin sensitivity, reducing weight, and alleviating oxidative stress. In modern Chinese medicine, 香格里拉谷维素胶囊, 纯净谷维素软胶囊, and 诺特博谷维素片 are some of the medicines marketed in China that contain gamma-oryzanol. This study aims to evaluate the effects of gamma-oryzanol on clinical hallmarks of PCOS. Also to compare the efficacy of gamma-oryzanol alone versus in combination with clomifene citrate.

Methods

In this study, PCOS was induced in a rat model using estradiol valerate. Gamma-oryzanol was then administered both alone and in combination with clomifene citrate.

Results

The effects of gamma-oryzanol on estrous cyclicity, fertility, histopathological alterations, estradiol and testosterone levels, and oxidative parameters were evaluated. The results showed that gamma-oryzanol, both alone and in combination with clomifene citrate, had protective effects against the estradiol valerate-induced PCOS rat model. The combination of gamma-oryzanol and clomifene citrate was particularly effective, showing significantly better results than the standard treatment group (clomifene citrate alone).

Discussion

These results suggest that gamma-oryzanol could be used in combination with existing standard treatments to enhance the management of PCOS. However, further molecular and clinical studies are needed to confirm these findings.

Background

The term "cancer" refers to illnesses in which cells can proliferate uncontrollably, infiltrate, and spread to various body organs. Since it has been used for thousands of years, traditional Chinese medicine (TCM) is now commonly regarded as an alternative for treating cancer. It has been demonstrated that Yangzheng Xiaoji (YX), a traditional Chinese medicine formulation, has anticancer effects in patients with different tumor types.

Method

Searches were conducted in several electronic databases from the year 2003 to 2024, including Pubmed, Google Scholar, Scopus, and Science Direct, to find evidence about YX. The purpose of this review is to provide an overview of YX's anticancer research findings.

Result

A result of the limited understanding of the fundamental mechanisms of action of the herbs, modern medicine frequently conflicts with traditional medicine, such as Chinese herbal medicine. Our research demonstrates the broad spectrum of anticancer potential of the YX formulation. Additionally, the particular YX component was also searched for anticancer potential.

Discussion

We have chosen to emphasize only some aspects of each YX ingredient's function in cancer therapy because it has been suggested that several processes are involved when applying TCM therapies. Furthermore, the effect of YX therapy on various malignancies is also covered. Additionally, we have emphasized YX treatment research that alters the tumor microenvironment and eradicates cancer.

Conclusion

The data gathered in this review will act as a strong basis for creating YX for cancer therapy.

Introduction

Insomnia is a chronic disease affecting a third of the global adult population. Hehuan Anshen Decoction (HHASD), an innovative formula derived from Traditional Chinese medicine, has demonstrated therapeutic efficacy in treating insomnia, however, the potential pharmacological mechanism underlying its anti-insomnia effects remains incompletely elucidated. This study aimed to explore the underlying mechanism of HHASD treatment in mice with insomnia induced by p-Chlorophenylalanine (PCPA).

Methods

The active constituents of HHASD were analysed by means of UPLCHRMS. PCPA mice were administered HHASD orally for 7 days. The anti-insomnia phenotype of HHASD were assessed by behavioral tests, encompassing the open field test and pentobarbital sodium-induced sleep test, alongside the measurement of hypothalamic 5-HT levels. Then, we conducted an in-depth analysis of specific ferroptosis markers, considering biochemistry, genetics and morphology. Additionally, ferroptosis inhibitor RSL3 was used to observe the underlying mechanism of the effects of HHASD.

Results

HHASD could effectively improve the insomnia behaviors induced by PCPA, resulting in increased movement trajectories, decreased sleep latency and prolonged sleep duration. Specifically, HHASD exerted a neuroprotective effect by enhancing the integrity of Nissl bodies in the hypothalamus of the PCPA mice. Mechanistic analysis revealed that HHASD could reverse the hypothalamic ferroptosis phenotype of insomnia mice by restoring the lowered levels of glutathione (GSH), inhibiting iron accumulation and elevated malondialdehyde (MDA), and mitigating mitochondrial cristae damage. Furthermore, HHASD enhanced the expression of SLC7A11 and GPX4 and reduced the ASCL4 in the hypothalamus, while the anti-insomnia effect of HHASD in the PCPA mice was eliminated by the GPX4 inhibitor RLS3.

Conclusion

HHASD ameliorates insomnia-related behaviors and protects against neuronal damage by suppressing ferroptosis by regulation GPX4 signaling. This study is not only a valuable attempt to explore the potential mechanism of Traditional Chinese formula but also will provide a novel targeted therapy for the treatment strategy of insomnia.

Introduction

Saikosaponin A (SSA), a triterpenoid saponin derived from Radix Bupleuri, is a prominent bioactive compound known for its therapeutic potential. Importantly, SSA is recognized for its widespread use in contemporary Chinese medicinal formulations. The current review highlights SSA's promising role in developing pharmaceuticals and dietary supplements for diverse medical applications, supported by extensive empirical evidence (2001–2024).

Methodology

Literature search across Google Scholar, Scopus, PubMed, and Web of Science, covering publications from 2001 to 2024, aimed to gather extensive information on the pharmacological properties of Saikosaponin A. Using keywords such as “Saikosaponin A,” “Oxidative stress,” “Cancer,” “Inflammation,” “Neuroprotection,” and “Apoptosis,” this review consolidates existing knowledge and offers potential avenues for future research.

Results

This study incorporates findings from various in vitro and in vivo investigations to evaluate SSA's efficacy across multiple health conditions, including cancer, inflammatory diseases, viral infections, cardiac ailments, and neurological disorders. The results demonstrate that SSA exhibits significant therapeutic effects in treating various cancers, mitigating inflammation, providing neuroprotection in conditions such as Parkinson's disease, epilepsy, and depression, combating influenza A virus, and aiding in obesity management.

Discussion

Conclusively, this review highlights the therapeutic potential of SSA, underscoring its importance in treating chronic diseases related to the central nervous system, neoplasms, and inflammatory pathways. Continued research into SSA could yield significant advancements in managing these conditions, reinforcing its value in both traditional and modern medical practices.

Introduction

In Traditional Chinese Medicine (TCM), Morinda citrifolia Linn. (Hai ba ji), is utilized for its various parts such as leaves, fruits, flowers, roots, and bark, serving as a tonic and addressing ailments including fever, skin, eye, throat, and gum issues, as well as nausea, vomiting, and neurological diseases. Previous research indicated that M. citrifolia Linn. fruit and its juice reduced ethanol-conditioned place preference (CPP) in mice, with scopoletin (SCOP) and rutin (RUT) proposed as the main bioactive compounds responsible for this effect. This study aimed to evaluate the impact of SCOP and RUT on ethanol reward using the CPP test in mice.

Methods

The CPP protocol consisted of a habituation phase spanning 3 days, a 1-day preconditioning phase, 10 days of conditioning, a rest day, and a post-conditioning day. The vehicle-saline control and vehicle-ethanol control groups received oral administration of a 1 % w/v solution of sodium carboxymethyl cellulose (CMC) at a dosage of 10 ml/kg. SCOP and RUT were administered orally at doses ranging from 0.05 to 1 mg/kg body weight (bw), while acamprosate (ACAM) was administered at a dosage of 300 mg/kg bw, all one hour before postconditioning. Statistical analyses utilized both repeated measures two-way and one-way ANOVA.

Results

Oral administration of SCOP (0.05, 0.1, and 0.5 mg/kg bw) and RUT (0.05 mg/kg bw) one hour before postconditioning testing on day 16 markedly reduced ethanol CPP in mice. Additionally, SCOP and RUT at all tested doses (0.05–1 mg/kg bw, p.o.) did not induce any changes in normal locomotor activity in mice.

Discussion

These results suggest that SCOP and RUT diminish ethanol reward in mice, underscoring the therapeutic potential of these phytochemicals in managing alcohol use disorder.

Introduction

Numerous plants in the Vernonia genus are used in Traditional Chinese Medicine (TCM) to treat a wide range of illnesses, such as pityriasis rubra pilaris, infections, wounds, dermatitis, mastitis, diarrhoea, and colds. These genera also have antibacterial, antipyretic, and anti-inflammatory properties. The current work sought to investigate the bactericidal and phytochemical characteristics of Vernonia squarrosa leaf extract and comprehend antibacterial action using molecular docking.

Methods

An in vitro study was carried out to investigate the antibacterial capabilities of V. squarrosa. HRLCMS analysis was conducted to determine the phytoconstituents of the chloroform extract (LC). For molecular docking validation, PyRx, an Open Babel integrated Auto Dock programme, was used.

Results

Present investigation reveals strong antibacterial activity against two tested gram-positive and gram-negative bacterial strains compared to other solvent extracts, LC at a higher concentration demonstrated a better response. Against Bacillus subtilis (20.05±0.88 mm) and Escherichia coli (20 ± 0.00 mm), the active components of the extracts formed the largest inhibitory zone followed by Pseudomonas aeruginosa (19.50±0.50 mm) and Staphylococcus aureus (14.33 ± 0.33 mm). The LC extract had lower minimum inhibitory concentrations (MIC) and stronger bactericidal activity than the other extracts.

Discussion

V. squarrosa's LC showed higher levels of antibacterial activity against the tested bacterial strains than other solvent extracts, most likely as a result of the presence of 31 chemical components, including flavonoids, glycosides, alkaloids, phenolics, and triterpenoids. Developing unique TCM formulations assume significance in global healthcare scenarios to combat bacterial infections and in this context, the current paper underlines the importance of the potent antimicrobial properties of chloroform extract of V. squarrosa. This study revealed that chloroform extract of V. squarrosa has a great deal of antibacterial activity.

Conclusion

According to the study, V. squarrosa leaf chloroform extract possesses antibacterial properties because of its active phytocompounds. Its wide range of bioactive components makes it a prime choice for developing novel formulations to neutralize threats of newly emerging strains of harmful bacteria. The aforementioned discoveries may deepen our comprehension of phenomenal wisdom and deep science associated with the legendary TCM.

Introduction

Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive loss of dopaminergic neurons in the substantia nigra. Despite extensive research, the etiology of PD remains elusive, and current treatments focus primarily on symptomatic relief rather than disease modification.

Methods

The papers were searched in Web of Science, Scopus, PubMed, PubMed Prime, Cochrane library, Sciencedirect and Google Scholar as web resources. This article includes information about tannins research and reviews in the treatment of PD. However, other paper related to CNS have been avoided.

Results

In recent years, there has been growing interest in exploring the therapeutic potential of natural compounds, such as tannins, for the management of PD. Tannins, polyphenolic compounds found abundantly in various plant species, have demonstrated neuroprotective effects through their antioxidant, anti-inflammatory, and metal chelating properties. This review provides a comprehensive overview of the current understanding of PD pathophysiology, existing treatment modalities, and the potential role of tannins in PD management. Additionally, recent advancements in the application of tannins, including in vitro and in vivo studies, clinical trials, and novel delivery systems, are discussed. Furthermore, challenges and future perspectives regarding the translation of tannin-based therapies into clinical practice are addressed.

Discussion

Overall, this review highlights the promising therapeutic potential of tannins in the treatment of Parkinson's disease and underscores the need for further research to elucidate their mechanisms of action and optimize their clinical efficacy.

Objective

To evaluate the synergistic effects and underlying mechanisms of WNT974 and artesunate (ART) combination therapy in the treatment of colorectal cancer (CRC).

Methods

We conducted an initial assessment of the synergistic impact of WNT974 and ART on cell viability using the MTT assay across eight CRC cell lines with diverse mutation statuses.Subsequently, a 3D in vitro model was utilized to confirm the synergistic effect of the combination. Flow cytometry was employed to analyze cell cycle distribution. The molecular mechanisms were further investigated by examining the expression levels of cell cycle-related proteins (p21, p27, and CDK2) and AKT activity through PCR and Western blot analyses. The in vivo efficacy of the combination therapy was evaluated using a xenograft mouse model of CRC.

Results

The combination of WNT974 and ART significantly reduced cell viability in all eight CRC cell lines, demonstrating a synergistic effect. Additionally, the combination exhibited synergy in inhibiting 3D spheroid growth. Cell cycle analysis revealed that the combination therapy induced a marked G1/G0 arrest through CDK2 inhibition, surpassing the efficacy of individual treatments. Molecular analysis indicated that the combination therapy upregulated p21 and p27 expression and reduced AKT activity. In vivo, the combination therapy significantly inhibited tumor growth in the xenograft mouse model, notably outperforming 5FU, the standard first-line drug for CRC.

Conclusion

The study highlights the synergistic anti-CRC effects of combining WNT974 and ART. This combination induces G1/G0 phase cell cycle arrest by cooperatively regulating p21, p27, and AKT, presenting a promising alternative to current CRC treatments. These findings elucidate the molecular basis of this interaction and provide a scientific foundation for advancing ART combined with WNT94 as a novel therapy for CRC, offering a potential new avenue.